Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

Bio-Tech fails under capitalism’s technocapitalist optimism. Obsession with profitability makes critical research ineffective.

Schmachtenberger 21 (Daniel, Founding member of The Consilience Project aimed at improving public sensemaking and dialogue, “The Case Against Naive Technocapitalist Optimism”, The Consilience Project, August 1, https://consilienceproject.org/the-case-against-naive-technocapitalist-optimism/)

Technocapitalism exists as a highly competitive marketplace of intangibles.

These intangibles include intellectual property such as software products, or access to proprietary “platforms” like Amazon Marketplace or app stores. Technocapitalist products may be defined typically as “disruptive innovations,” in the words of Clayton Christensen: they are ideas that begin as inferior alternatives to existing offerings, and enter play either at the foot of the market or in a new market altogether. The underlying technology is significant because it can provide cost-effective, novel competition to ideas that are already in production.[26] Research-intensive industries, such as computing and biotechnology, are at the forefront of these efforts. With public funding for scientific research on a steady decline since the latter half of the 20th century, private funding is increasingly needed for viability.[27] In this environment, research must consistently prove its value to funders in order to persist. A well-known example of this, extrapolated from data gathered in the 1990s, is that over 75% of all medical research is privately funded. As a result, rare disease research relies disproportionately on private funding.[28] This effect is mirrored in other fields, and has increased in proportion: between 2012 and 2016, academic-industry collaborations more than doubled globally.[29] The pharmaceutical industry is notoriously fickle about what constitutes marketability and is therefore likely to pass over areas of research that are not clearly profitable.[30]

Private funding can offer flexibility by bypassing public bureaucracy, and technocapitalist campaigns often emerge as efforts to reduce red tape.[31] For example, when the Gates Foundation began funding research into experimental pandemic response efforts, their proposed solution until approximately 2015 was for a NATO-like organization to handle public health policy, and they worked extensively with the WHO and the GAVI vaccine alliance, a public-private enterprise. However, the WHO’s sluggish Ebola response between 2014 and 2016 prompted the Gates Foundation in 2017 to provide backing for CEPI, a vaccine research accelerator, and in 2020, the Gates Foundation’s COVID response efforts largely bypassed intergovernmental organizations, instead utilizing direct, private funding to pivot existing research initiatives into COVID testing trials. These redirections of private research provided data that outstripped the WHO by a critical few months before the FDA halted the program due to regulatory approval issues.[32]

A cause for concern, however, is that private funding has private goals, and that this may impact trustworthiness of private research. Objective empiricism is questionable when it is connected to corporate objectives, and this has the potential to reduce public trust in the research process. Privately funded studies are demonstratively more likely to reach conclusions that favor sponsors’ interests. One analysis of medical industry funding found that privately-funded research is four times more likely to provide a favorable assessment of a drug than publicly-funded research.[33] It also appears that the public is, generally speaking, in on the plot. A meta-analysis of pharmaceutical trials suggests that trials with disclosed financial ties to industry are perceived as “less interesting, important, relevant, valid, and believable” than those without financial disclosures. Though a consistent quantitative effect is difficult to document due a limited sample size, a significant portion of patients and clinicians may feel that disclosed financial ties reduce research quality, and can discourage patients from participating.[34]

Notably, corporations themselves are also experiencing a reduction in internal science funding. The proportion of corporate funding allocated toward the research side of industrial R&D dropped from 28% in 1985 to 20% in 2015. The same review of scientific publications found that the rate of papers being published by corporations dropped significantly between 1980 and 2010, indicating that it is most cost-effective for companies to rely on existing data as opposed to producing new data.[35] This is because market pressures favor applied research in the interest of greenlighting products, not higher-risk investments in foundational science that are likely to pay off at a later date. In the interest of budget conservation, research may be dropped. Patents increase the value of innovations, and in turn stimulate continued R&D in the interest of “inventing around” (i.e. around existing innovations). As a result, there is a disproportionate focus on development rather than research as the most profitable approach for a corporation.[36]

The balance of public relations and institutional respectability is delicate.

If both the public and traditional private sectors are experiencing funding squeezes, the technocapitalist investment sector should be a great source of support for the technological and scientific communities. However, the technocapitalist “disruptor” efforts are subject to the same issues choking industry funding: they favor low-risk research with high payoffs. Research that requires a fifteen-year timeline to produce tangible effects is passed over in favor of disruptive options. These initiatives can have limited shelf lives due to regulatory issues or poor adoption rates.[37]

Sign in to recut, update, or save this card.